Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Cushing Syndrome 2ACTH Syndrome, Ectopic 2Hypertension 1Adrenal Cortex Neoplasms 1Acth-Independent Macronodular Adrenal Hyperplasia 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Osilodrostat × Clear all
NCT07247162 2025-12-10

LINC CARE

RECORDATI GROUP

Phase 4 Not yet recruiting
63 enrolled

ACTH Syndrome, Ectopic, Cushing Syndrome, Hypertension

NCT02468193 2020-05-06

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Novartis

Phase 2 Completed
9 enrolled 22 charts

Acth-Independent Macronodular Adrenal Hyperplasia, ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡